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INTRODUCTION
Mood disorders are relatively common mental illnesses that 
are notorious for high disease burden and chronicity.1,2 Dis-
ease course and treatment responses in mood disorders varies 
from person to person because they are associated with an in-
terplay of socio-cultural and genetic-biological factors. Major 
mood disorders, including major depressive disorder (MDD) 
and bipolar disorder (BD), have profound social impacts due 
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to increased suicide risk and decreased functional levels and 
quality of life.3-6 Despite recent advancements in the diagnosis 
and treatment of mood disorders, it is still difficult to predict 
treatment response and disease courses. Delayed diagnosis 
and diagnostic conversion from MDD to BD are making clini-
cal decision making more difficult. Furthermore, long-term 
effects of currently available treatments on mood disorders 
are unclear. Novel approaches for early detection of and inter-
vention for mood disorders are necessary. 
A better understanding of long-term clinical courses is cru-
cial for finding clinically meaningful biomarkers for early di-
agnosis and intervention. Cohort studies can provide valuable 
information on the clinical courses of mood disorders and 
the effects of treatments on the course of mood disorders.7 
Various prior cohort studies of mood disorders are available, 
yet each study has limitations in explaining the complexity of 
clinical presentation of mood disorders. 
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Cohort Studies for Mood Disorders
In this paper, as part of a preliminary investigation for a 
prospective cohort study of Korean patients with mood dis-
orders, we reviewed all currently available findings from major 
cohort studies of patients with mood disorders, including 
MDD and BD Through this review process, we propose an ef-
ficient study design that is suitable for capturing the real-world 
clinical setting in Korea.
METHODS
We searched the currently available literature based on co-
hort studies of mood disorders using databases such as 
PubMed and KoreaMed. The search for relevant publications 
was carried out using the terms ‘cohort study’, ‘design’, ‘meth-
odology’, ‘mood disorder’, ‘depression’, and ‘bipolar disorder’. 
We had screened all abstracts of publications through the 
two databases. As this review focused on adult populations, 
we excluded literature involving children, adolescents and the 
elderly. We included cohort studies that followed clinical 
courses of mood disorders using relatively standardized meth-
odology. We excluded any literature that was not directly asso-
ciated with mood disorders or conducted in a single center. 
After a careful review process, we selected eight major cohort 
studies using standardized evaluation methods for this re-
view. We explored the design and methodology of each study 
and summarized the studies’ major findings and limitations. 
RESULTS (Table 1)
Naturalistic cohort study with community population
The Lundby study
The Lundby study is a longitudinal cohort study of a geo-
graphically defined population consisting of 3563 subjects. 
This study was designed to investigate the distribution of per-
sonality traits and mental disorders.8 The first field investiga-
tion started in 1947, and another investigation began in 1957 
to include additional participants who had moved into the 
geographic area. Ninety-nine percent of the subjects were in-
terviewed by psychiatrists. The interviews, most of which were 
conducted face-to-face, were carried out in 1947, 1957, 1972 
and 1997. 
At each time point, subjects participated in a semi-struc-
tured interview consisting of questions about their sociode-
mographic background, somatic health, mental health, medi-
cal service use, and life events that had taken place during the 
period since the last interview. Along with to the face-to-face 
interview, investigators contacted key informants to obtain ad-
ditional reliable information. Also, investigators had access to 
case notes and several registers, including the Patient Register, 
which contained information about all inpatient care in Swe-
den from 1972 to 1997.9 The final evaluations of the clinical 
diagnoses took place after collecting all available information 
and determining a best-estimate diagnosis. 
Since the DSM system10 was not available at the time of the 
study, the main categories of the Lundby diagnostic system are: 
depression, anxiety disorders, tiredness, mixed neurosis, schizo-
phrenia, other psychoses, organic syndrome, and dementia. 
This is a hierarchical diagnostic system; that is, only one diag-
nosis per episode was registered. The Lundby diagnosis of de-
pression remained unchanged during the study period. 
After excluding subjects with preexisting alcohol problems 
or depression, 344 subjects (116 males, 228 females) who ex-
perienced their first depressive episode between 1947 and 
1997 were examined to explore long-term courses of depres-
sion.11 The median age of the first onset of depression was 
around 35 years for individuals followed for 30–49 years. The 
recurrence rate was approximately 40% and ranged from 17% 
to 76% depending on the follow-up duration. A transition to 
diagnoses other than depression occurred for 21% of the to-
tal sample, with alcohol disorders in 7% and BD in 2%. Only 
5% committed suicide; here, male gender and severity of de-
pression were significant risk factors.
Limitation
The main limitation of the Lundby study is the diagnostic 
system applied. Taking into consideration the high comorbid-
ity of mood disorders, a hierarchical system is not sufficient 
to evaluate the complex nature of mood disorders. Also, the 
interval of follow-up evaluations was too sparse to explore 
clinical courses in detail.12 
The Zurich study
The Zurich study13 selected 4547 participants, 2201 males 
and 2346 females aged 19 and 20, respectively, from the can-
ton of Zurich in Switzerland in 1978. At baseline, they were 
screened with the Symptom Checklist 90-R (SCL-90-R)14 in 
order to select for participants with high global severity indi-
ces (GSI) who would be more likely to develop psychiatric 
syndromes. A stratified random sample of 591 individuals (292 
males, 299 females), two-thirds of whom were high scorers 
(defined as those scoring above the 85th percentile on the 
GSI), was selected for a follow-up interview. Following the 
initial screening in 1978, six subsequent interview waves were 
conducted across 20 years. 
Psychiatric residents and clinical psychologists carried out 
the follow-up interviews using the Structured Psychopatho-
logical Interview and Rating of the Social Consequences for 
Epidemiology (SPIKE). The SPIKE evaluates a broad range of 
psychiatric and somatic syndromes and symptoms through 
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questions regarding duration, frequency, treatment and sub-
jective impairment and distress. All psychiatric diagnoses 
were made based on DSM-III-R and DSM-IV criteria.10
Major findings
The Zurich cohort study provided a valuable opportunity 
to examine the chronicity and diagnostic stability of mood 
disorders.15 The presence of MDD predicted heart complica-
tions and an increase in long-term body weight variability.16 
Comorbid anxiety and depression tended to be more stable 
than either syndrome alone, suggesting the importance of co-
morbidity in clinical courses. Melancholic depression showed 
a more severe clinical course than atypical depression. Chron-
ic depression, during which a major depressive episode lasts 
longer than 2 years, was associated with an earlier onset, worse 
clinical symptoms, more frequent psychiatric comorbidity, and 
poorer functional level and physical condition relative to epi-
sodic depression.17 Combined agitated and retarded major 
depressive states were associated with a transition to BD, while 
pure agitated depression was less frequently associated with 
BD.18 Relative to MDD, BD was more closely associated with 
the development of alcohol and benzodiazepine use disor-
ders.19 
Limitation
The Zurich cohort study explored clinical courses of mood 
disorders among patients ages 20 to 40, which limits the gen-
eralizability of the findings to people over 40 years old. The 
relatively infrequent evaluations and lack of biological mea-
sures limit the applicability of study findings. 
Naturalistic cohort study with clinical population
National Institute of Mental Health Collaborative 
Depression Study
The NIMH CDS is the lengthiest longitudinal study of 
clinical courses of mood disorders. Inpatients and outpatients 
who were experiencing an active affective episode were re-
cruited from 5 tertiary care centers in the United States be-
tween 1978 and 1981.20 A total of 1,031 subjects with MDD, 
manic disorder, schizoaffective disorder and intermittent de-
pressive disorder were enrolled, and long term follow-up eval-
uations were conducted for 31 years. 
At the initial intake, a semi-structured interview using the 
Schedule for Affective Disorders and Schizophrenia (SADS)21 
and the Research Diagnostic Criteria (RDC)22 was conducted 
to confirm subjects’ diagnoses. Functional levels, a personali-
ty battery, and family history were also collected. The follow-
up evaluations were based on the Longitudinal Interval Fol-
low-up Evaluation (LIFE) ratings.23 The LIFE ratings determine 
the symptom severity of each affective disorder on a 6-point 
Likert scale based on whether symptoms meet RDC’s defi-
nite criteria (1: usual self; 2: residual; 3: partial remission; 4: 
marked; 5: definite criteria; and 6: definite criteria, severe). 
The Longitudinal Interval Follow-up Evaluation Range of 
Impaired Functioning Tool (LIFE-RIFT)24 evaluates subjects’ 
functional levels in the domains of work, interpersonal rela-
tions, recreation, and global satisfaction on a 5-point Likert 
scale (1=no impairment; 5=severe impairment). Trained rat-
ers interviewed participants every 6 months for the first 5 
years and yearly thereafter, using variations of the LIFE and 
LIFE-LIFT ratings. 
Major finding 
A major strength of the CDS is that patients having diverse 
affective spectrum diseases, including MDD, bipolar I disor-
der, and bipolar II disorder, were recruited together and eval-
uated using uniform evaluation methods. As a result, we were 
able to see differences between the courses of these affective 
spectrum diseases. Both MDD and BD were chronic and re-
current disorders that caused significant psychosocial disabil-
ity.25-27 Most subjects experienced subthreshold residual symp-
toms even when they were not in an acute episode, which had 
negative effects on their prognosis.28 Comorbid anxiety, sub-
stance use disorder, double depression and longer episodes pre-
dicted negative treatment responses.29 In BD, depressive epi-
sodes and symptoms dominated overall clinical courses and 
were more disabling than (hypo)manic episodes and symp-
toms.27,30-32 Strikingly, one-fourth of subjects with MDD even-
tually became diagnosed with BD.33 The main risk factor for 
the transition was subthreshold manic/hypomanic symptoms.
The CDS established the foundation for biological and clini-
cal research of mood disorders through a comprehensive long-
term evaluation using phenomenological, diagnostic, and genetic 
approaches. Major findings from the CDS have contributed to 
the study design of treatment strategies for mood disorders, 
such as the Sequenced Treatment Alternatives to Relieve De-
pression (STAR*D)34 and the Systematic Treatment Enhance-
ment Program for Bipolar Disorder (STEP-BD).35
Limitations
Only Caucasians were included in the genetic studies, which 
limits the generalizability of the study findings. In addition, 
an early-age onset population was not included, so the life-
time course of mood disorder from the early period of mood 
disorders was not explored. Although the study was done 
prospectively, each follow-up evaluation using the LIFE and 
LIFE-RIFT was a retrospective evaluation that took place ev-
ery 6 months or 1 year. Consequently, the follow-up evalua-
tions may have been prone to recall biases. Although LIFE had 
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a high intraclass correlation coefficient, more detailed and ob-
jective assessments for mood symptoms and suicidality at 
each follow-up period were not included in the study. This 
could have compensated for this major limitation of the LIFE 
and LIFE-RIFT evaluation. 
Netherlands Study of Depression/Anxiety
The NESDA is a multi-site naturalistic cohort study de-
scribing the long-term course and consequences of depres-
sive and anxiety disorders.36 The NESDA followed 2981 par-
ticipants ages 18 to 65 for eight years. In order to increase the 
generalizability of the study, subjects were recruited from var-
ious health care settings (community, primary care, and spe-
cialized mental health care) and at various stages of the dis-
order’s developmental history (normal, high familial risk, 
subthreshold disorders, first and recurrent episodes). Among 
all participants, 1701 subjects had depression (with or without 
a comorbid anxiety disorder), had a lifetime diagnosis, or 
were at risk due to a family history of subthreshold symptoms.
The Composite Interview Diagnostic Instrument (CIDI)-
Lifetime Version37 was used to confirm the diagnoses based on 
DSM-IV criteria.10 Information from a detailed clinical inter-
view, self-report questionnaire, medical examination, brain 
functional magnetic resonance imaging (fMRI), cognitive 
computer task and blood and saliva samples were collected 
at baseline. 
The follow-up evaluations were conducted at four time 
points: one year, two years, four years, and eight years after the 
initial assessments. The one-year follow-up assessment con-
sists of questionnaires to determine demographic changes, re-
cent life events and the course and consequences of anxiety 
and depression symptoms. The two-year follow-up assess-
ment includes a face-to-face clinic visit in addition to the ques-
tionnaires given at the one-year follow-up assessment. During 
the clinic visit, participants complete a clinical interview, com-
puterized cognitive tasks, and an additional questionnaire re-
garding seasonality. 
Major findings
So far, findings from the two-year follow-up assessments 
are available. The comorbid depression-anxiety group showed 
a more chronic course than the pure depression group. Pre-
dictors of poor clinical course were severity and duration of 
index episode, comorbidity, earlier onset age, and older age. 
The NESDA incorporates a comprehensive clinical and bio-
logical evaluation that offers a unique opportunity to explore 
the long-term course of depression. Contrary to other cohort 
studies of populations with mood disorders, the NESDA in-
creases the generalizability of study findings by including a 
variety of clinical populations. In addition, the study utilizes 
various biological measures, such as cognitive and neuroim-
aging evaluations, which can be valuable biomarkers in de-
termining clinical outcomes of mood disorders. 
Limitations
The main limitation of the NESDA study is the lack of fre-
quent evaluations during the observational period. Since fol-
low-up assessments are conducted at one-year, two-year, four-
year, and eight-year time points, we cannot evaluate detailed 
mood fluctuations during each time interval. Recall biases are 
also inevitable in this study design. 
Cohort studies with clinical population designed for 
clinical trials
The NIMH Sequenced Treatment Alternatives to Relieve 
Depression Study
The NIMH-funded STAR*D study is a multisite, prospec-
tive, randomized, multistep clinical trial of patients with non-
psychotic MDD.34 The STAR*D aimed to determine effective-
ness of different treatments, including non-pharmacological 
treatments, for MDD that did not respond to the initial treat-
ment. The STAR*D also aimed to describe the incidence, na-
ture, and course of symptoms and functioning for those en-
tering the 12-month naturalistic follow-up.38
At baseline, the Psychiatric Diagnostic Screening Question-
naire (PDSQ)39 was used to confirm DSM-IV based psychiat-
ric diagnoses. The 17-item Hamilton Rating Scale for Depres-
sion (HRSD17),40 the 16-item Quick Inventory of Depressive 
Symptomatology-Clinician Rating (QIDS-CR) and the Quick 
Inventory of Depressive Symptomatology-Self-Report (QIDS-
SR)41 were used to determine the severity of depression symp-
toms. Clinical Global Impression-Improvement,42 QIDS-CR, 
QIDS-SR and questionnaires regarding side effects and func-
tional levels were used for follow-up evaluation. The primary 
outcome measure was the HRSD17, which was administered 
at the end of each treatment level by independent phone in-
terviewers.
The STAR*D used broad inclusion and minimal exclusion 
criteria; subjects between ages 18 and 75 who met the criteria 
for single or recurrent non-psychotic MDD with a HRSD 
score less than or equal to 14 were included in the study. Par-
ticipants with an adequate symptomatic response entered the 
12-month naturalistic follow-up phase, which involved brief 
monthly as well as more thorough quarterly assessments. 
The study also collected subjects’ blood samples for genetic 
analysis.
Major findings
The STAR*D study provided crucial information on decid-
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ing treatment sequence through detailed treatment responses 
and clinical presentations of individuals with non-psychotic 
MDD.43 It also revealed clinical factors associated with treat-
ment responses and prognosis. A total of 4351 subjects from 
both primary and specialty care practices were enrolled in the 
study. Remission rates for treatment levels 1 through 4 were 
36.8%, 30.6%, 13.7% and 13.0%, respectively.44 There was no 
difference in effectiveness between any treatments at any treat-
ment level. Patients with longer index episodes, more concur-
rent psychiatric or general medical disorders, and/or lower 
measures of baseline function were less likely to achieve remis-
sion. There were no major differences in outcomes between pa-
tients treated in primary versus specialist care,45 nor were there 
significant differences in depression rating scores obtained 
through clinician ratings versus self-report. This study also 
evaluated various clinical trials, including non-pharmacological 
treatment for treatment-resistant depression, none of which 
showed superiority over other treatment modalities.46-48 
In addition to clinical trials, the STAR*D also explored vari-
ous clinical characteristics that could affect treatment re-
sponses and the prognosis of MDD. As reflected in the DSM-5 
diagnostic system, the study confirmed the importance of 
anxiety in clinical courses of MDD.49 About 20% of partici-
pants with MDD had chronic depression,50 which exhibited 
poorer prognosis. Recent manic-like symptoms and family 
histories of BD were associated with conversion to BD, while 
irritability and antidepressant resistance were not associated 
with the conversion.51,52 General medical comorbid conditions 
were not uncommon in MDD, and they affected the severity 
of the depression.53,54 Age of onset55 and episode duration56 
did not change the likelihood of remission. Using blood sam-
ples collected from subjects, genetic association studies inte-
grating detailed clinical observations and genetic variances 
were conducted.57-64 
Limitations
Because the STAR*D study aimed to conduct clinical trials 
from the outset, there may have been a bias in the recruitment 
processes. Detailed clinical observation is one of the major 
strengths of the STAR*D study, but it also can limit initial 
study participation. In addition, populations with psychotic 
depression, not uncommon in clinical practice, were not in-
cluded in the study. 
The NIMH-funded Systematic Treatment Enhancement 
Program for Bipolar Disorder
The STEP-BD is a multisite and prospective treatment study 
for BD.35 Similar to the STAR*D project for non-psychotic 
MDD, the STEP-BD projects aimed to determine the effective-
ness of various treatment modalities for BD in both the acute 
and maintenance phases. Like the STAR*D project, the STEP-
BD also aimed to observe a naturalistic clinical course for 12 
months. It incorporated both randomized controlled clinical 
studies and uncontrolled, evidence-based clinical care.65 
Considering the complexity of the clinical presentation of 
BD, the STEP-BD was designed to include the full spectrum 
of bipolar patients seeking clinical care. All patients with bi-
polar subtypes, including bipolar I, II, bipolar not otherwise 
specified (NOS), and cyclothymia, who were in any phase of 
the illness for longer than 15 years were able to take part in the 
study. Regardless of whether patients participated in the nat-
uralistic study or the randomized trials, they received identi-
cal ongoing assessments of treatment and outcome informa-
tion. Blood samples were also collected for the genetic analyses. 
Diagnoses were confirmed through the administration of 
the Mini International Neuropsychiatric Interview (MINI)66 
and a standardized affective disorder evaluation (ADE)67 by a 
clinical specialist (a psychologist or social worker) and the 
treating psychiatrist, respectively. For symptom evaluation, 
various questionnaires were used to consider the complex 
symptom presentation of BD; interviewers administered the 
Montgomery-Asberg Depression Rating Scale (MADRS),68 
Young Mania Rating Scale (YMRS),69 Liebowitz Social Pho-
bia Scale,70 Panic Disorder Severity Scale,71 and Yale-Brown 
Obsessive Compulsive Scale.72 Subjects also completed vari-
ous self-report questionnaires, including the Beck Depression 
Inventory Version II (BDI-II),73 NEO Five-Factor Inventory,74 
ADHD Symptom Checklist, Eating Disorder Inventory, Fear 
Questionnaire, Beck Anxiety Inventory,75 Beck Hopelessness 
Scale, and SF-36 Health Survey.76 These questionnaires and 
rating scales were utilized for both the baseline and follow-
up assessments. The YMRS and the MADRS were the pri-
mary assessments of mood symptoms. Independent study 
assessments were scheduled at baseline and quarterly for the 
first year and then semiannually for up to 2 years. 
Major findings
A total of 4,361 subjects with bipolar spectrum disorder 
across 22 clinical sites in the United States were enrolled in the 
study. The STEP-BD study explored the efficacy of antide-
pressant use for BD, which has been controversial. In general, 
antidepressant use had neither benefit nor risk relative to the 
use of mood stabilizer alone.77 In a randomized study, patients 
who successfully recovered with both antidepressants and 
mood stabilizers were assigned to either the antidepressant 
plus mood stabilizer or the mood stabilizer alone treatment 
groups; no significant difference in the recurrence rate or the 
duration of remission was observed between the two groups.78 
However, in naturalistic studies, adjunctive antidepressant use 
was associated with increased mania symptom severity and 
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did not appear to reduce the time to recovery compared to 
treatment with mood stabilizer alone.79 Antidepressant use 
also exacerbated the clinical course of rapid cycling BD but 
was not associated with the development of suicidality.80 
Regarding treatment-resistant bipolar depression, a ran-
domized study was conducted to compare the effectiveness of 
lamotrigine, inositol, and risperidone. Although significant 
statistical differences were found in the primary analysis, la-
motrigine was more effective in terms of CGI and functional 
levels in the post-hoc analysis.81 The study also explored the 
efficacy of psychosocial intervention for BD. Intensive psy-
chosocial intervention, such as interpersonal and social 
rhythm therapy, cognitive behavior therapy, and family-fo-
cused therapy, enhanced functioning and life satisfaction in 
patients with BD.82 
In a naturalistic study, patients with BD showed a high dis-
ease burden even during standard clinical care. Among the 
1469 patients who were symptomatic at study entry, 858 (58%) 
subsequently achieved remission during follow-up.83 Nearly 
50% of these patients experienced recurrence during the 2 
years of follow-up. Residual mood symptoms at initial recov-
ery were associated with increased risk of recurrence. Although 
this is generally consistent with other reports, it suggests that 
the predominance of depressive relapse over manic relapse is 
substantially lower than was reported in the CDS study. 
The study also confirmed the complex disease presenta-
tion of BD. BD showed high rates of psychiatric and medical 
comorbid conditions,84 which were associated with poorer clin-
ical courses. Mixed features were common,85 and anxiety co-
morbidity increased suicide risk86 and worsened clinical cours-
es.87 Polypharmacy was also very common,88 and about 10% of 
patients were treated with the second-generation atypical an-
tipsychotics.89 Similar to the STAR*D study, genetic studies 
are actively being done in combination with sophisticated 
phenotype definition using the database.90-94 
Limitations
Also similar to the STAR*D study, participants in the STEP-
BD may not be representative of the general population with 
BD. In order to reflect the real-world clinical setting, patients 
who visited and sought treatment at the study sites were re-
cruited. Thus, this study’s population may be different from 
the population of the epidemiological study. Additionally, al-
though the study team made an effort to recruit people with-
in the minority population, Asian and Latino subjects were 
underrepresented. 
The Stanley Foundation Bipolar treatment outcome 
Network
The NIMH SFBN95 is a multisite clinical trials network 
that has been established to determine the relative efficacy of 
treatments for BDs that can address a wide range of variants 
and comorbidities of disease, which are the main character-
istics of BD. Subjects were recruited from four sites in the 
United States (Los Angeles, Dallas, Cincinnati, and Bethes-
da) and one site in Europe (Utrecht, Netherlands). All partic-
ipants were community-based subjects diagnosed with either 
BD I, II or not otherwise specified (NOS). The network was 
designed to conduct multi-level randomized controlled clini-
cal trials. More than 600 subjects were recruited, and 125 of 
these subjects participated in the randomized controlled clini-
cal trials. 
At baseline, all patients received the Structured Clinical In-
terview (SCID) for DSM-IV, Research Version (SCID-P).96 So-
cio-demographic and clinical information were collected 
through self-report questionnaires and an individual interview 
with a clinician. 
The NIMH Life Chart Manual for recurrent affective ill-
ness (NIMH-LCM)97 was used for long-term assessment. In 
the LCM self-version of prospective ratings (LCM-S/P),98 
each subject was instructed to record daily mood changes as 
well as functional levels and important life events. The clini-
cian integrated information from the LCM-S/P and inter-
view and finalized the NIMH Clinician version of the Prospec-
tive ratings (the NIMH-LCM-C/P).98 Moreover, additional 
information was collected through the 30-item Inventory for 
Depressive Symptomatology (IDS)99 for depression, the Young 
Mania Rating Scale (YMRS) for mania, the Positive and Neg-
ative Syndrome Scale (PANSS)100 for psychosis, the Global 
Assessment of Functional Scale (GAF)101 for social and occu-
pational functioning, and the Life Functioning Questionnaire 
(LFQ)102 for quality of life. 
Major findings
The SFBN included three double blind, randomized, con-
trolled studies on adjunctive agents for BD103: 1) adjunctive 
use of bupropion, sertraline and venlafaxine; 2) omega-3 ver-
sus placebo; and 3) modafinil versus placebo. Adjunctive use 
of antidepressants confirmed the risk of (hypo)manic switch 
in antidepressant use, which occurred less often in bipolar II 
disorder compared to bipolar I disorder.104 Among the three 
antidepressants examined, venlafaxine was associated with 
the highest risk of (hypo)manic switch.105 In the study on ad-
junctive use of omega-3, there was no significant difference 
in mood systems between the use of omega-3 and the place-
bo,106 while modafinil trials showed significant improvement 
of depressive symptoms compared to the placebo trials.107 
Also, two open randomized trials (tranylcypromine vs. la-
motrigine; sibutramine vs. topiramate) were conducted; tran-
ylcypromine showed promising efficacy in treating depres-
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sive symptoms compared to lamotrigine.108 Both sibutramine 
and topiramate, however, had significant side effects, such as 
weight loss. Topiramate had a higher discontinuation rate. In 
addition to randomized trials, numerous open-label, naturalis-
tic case series on adjunctive use of anticonvulsants (gabapen-
tin, zonisamide, levetiracetam, topiramate, lamotrigine, ti-
agabine and oxcarbazepine)109-112 and atypical antipsychotics 
(olanzapine, risperidone, quetiapine, clozapine and aripipra-
zole)113,114 were reported. 
The study also confirmed the chronic and recurrent nature 
of BD. A majority of subjects had a considerable degree of re-
sidual illness-related morbidity, with a three-fold greater 
amount of time spent depressed than manic.103 The study also 
found that there was a time delay of more than a decade be-
tween the onset of symptoms that met the full criteria of the 
mood disorder and the onset of first treatment. Early life ad-
versities (i.e., physical or sexual abuse) and a positive family 
history of mood disorders were associated with the early on-
set of BD.115 Both medical and psychiatric comorbidity were 
very common among the subjects.116 The severity of mood 
disorders was associated with having experienced mood epi-
sodes more than 10 times, a family history of drug abuse, and 
poor occupational functioning. The study also found that gen-
der affected disease presentation.117-119
Limitations
The study did not collect any biological samples to deter-
mine a biomarker for the clinical courses of BD. Thorough 
evaluation through academic or tertiary-referral centers may 
limit recruiting samples that can represent bipolar disorder in 
general. More importantly, subjects in the study had the ill-
ness for an average of 20 years, so study findings may not be 
generalizable to those in a relatively early phase of the illness. 
In particular, considering the fact that most illness variables 
were gathered through self-report questionnaire and inter-
views, reliability regarding the disease course may be lower 
than expected.
The Clinical Research Center for Depression study
The Clinical Research Center for Depression (CRES-
CEND) study is a 9-year observational collaborative prospec-
tive cohort study examining clinical outcomes in patients 
with depressive disorders in Korea.120 From January 2006 to 
August 2008, 1,183 participants were enrolled in the CRES-
CEND study from 18 hospitals throughout Korea. The CRE-
SCEND study endorsed a wide inclusion criteria; participants 
were over 7 years old and met the criteria for either MDD, 
dysthymic disorder, or depressive disorder, not otherwise 
specified (NOS), as determined by the SCID.96
The CRESCEND study included two phases with a follow-
up period of 9 years. In phase I, which lasted a year, each eli-
gible participant visited the hospital and was assessed at 1, 2, 
4, 8, 12, 24, and 52 weeks after baseline. During phase II, an 
extension of phase I, all participants were given an annual 
evaluation from year 1 (or the end of phase I) to year 9. 
A diagnostic evaluation, retrospective personal history of 
medical or psychiatric illnesses and treatment, and socio-ep-
idemiologic clinical data were collected at baseline. Clinical, 
social, and functional outcomes of the treatment were evalu-
ated with clinician- and self-administered measures during 
each visit. The clinician-administered measures included the 
CGI,42 the HRSD17,40 the Hamilton Anxiety Rating Scale 
(HAMA),121 the Brief Psychiatric Rating Scale (BPRS),122 and 
the Social and Occupational Functioning Assessment Scale 
(SOFAS).10 The self-administered measures consisted of the 
BDI-II,73 the Scale for Suicidal Ideation (SSI),123 and the ab-
breviated version of the World Health Organization Quality 
of Life assessment instrument (WHO-QOL-BREF).124
Major findings
The CRESCEND study is the first long-term prospective 
collaborative observational cohort study investigating the 
natural course and outcome for depressive patients in Korea. 
Baseline data from the study showed distinct characteristics of 
depression in Korea. Subjects with depression in Korea showed 
an older age of onset, more frequent histories of suicide at-
tempts and lower rates of family history of depression than 
previous studies in the Western countries.125 These character-
istics may be associated with biological and sociocultural 
characteristics of Korean MDD, with important implications 
for treatment plans and courses. The phase II follow-up as-
sessments are currently in progress. The remission rate after 
12 weeks of antidepressant treatment was 31.4%; female sub-
jects without a history of prior suicide attempt and with low 
baseline anxiety were found to have a higher remission 
rate.126,127 
Limitations
The study included all spectrums of depression; however, 
it did not include patients with BDs. About three-fourths of 
the participants in the CRESCEND study were recruited 
from outpatient settings, which may cause selection bias. 
CONCLUSION
So far, various cohort studies on mood disorders provided 
crucial information on the complex course of mood disor-
ders, building a foundation for clinical and biological research. 
However, there are several limitations in directly applying 
the study findings to real world clinical settings. In particular, 
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most studies explored clinical courses of populations with 
depression and BD separately, even though there has been 
controversy over whether the two diseases are within the 
same spectrum or have distinct neurobiological backgrounds. 
Considering the heterogeneous illness presentation and the 
transition from unipolar depression to bipolar disorder, 
which is not uncommon, it would be preferable to apply loose 
criteria using standardized evaluation methods to include a 
broad range of patients with mood disorders. In order to un-
derstand the detailed clinical course, close observation is 
necessary, and follow-ups should occur more frequently. 
Previous clinical trials have generally gathered detailed infor-
mation on the course, but there may have been a potential 
bias in their recruitment process. Regular naturalistic follow-
up evaluations will give us the best opportunity to observe 
the clinical course more closely. Moreover, it is ideal to have 
both an objective mood rating and a functional level evalua-
tion during the evaluation visits. In addition, it is important 
to observe the early stages of illnesses to determine factors as-
sociated with chronicity or recurrence. In order to apply clini-
cal information from naturalistic observations to early detec-
tion and treatment, biological samples should be collected at 
the same time. Aside from the CRESCEND study, the major-
ity of participants in cohort studies were Caucasian, so the 
biopsychosocial characteristics of Asian populations with 
mood disorders have not been thoroughly investigated. An 
innovative cohort study that can serve as a platform for trans-
lational research for treatment and prevention of mood disor-
ders is critical in determining clinical, psychosocial, neurobi-
ological, and genetic factors that are associated with long-
term course and consequences of mood disorders in Korean 
patients. 
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